Daesung Microbiological Labs. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 11:52 pm EST
Share
Daesung Microbiological Labs. Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 5,662.41 million compared to KRW 4,956.12 million a year ago. Net loss was KRW 1,130.82 million compared to KRW 16.28 million a year ago. Basic loss per share from continuing operations was KRW 298 compared to KRW 4 a year ago. Basic loss per share was KRW 298 compared to KRW 4 a year ago.
For the nine months, negative sales was KRW 0.00038 million compared to KRW 0.00034 million a year ago. Net loss was KRW 637.68 million compared to net income of KRW 1,739.45 million a year ago. Basic loss per share from continuing operations was KRW 168 compared to basic earnings per share from continuing operations of KRW 457 a year ago. Basic loss per share was KRW 168 compared to basic earnings per share of KRW 457 a year ago.
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. is a Korea-based company mainly engaged in the manufacture of animal pharmaceuticals. The Companyâs products consist of vaccines, antibiotics, antibacterials, anthelminthics, mastitis ointments, disinfectants, probiotics and enzyme products, teat dipping disinfectants, metabolites, nutrients, and biologicals used for prevention and treatment of diseases for cattle, swine, poultries and canines. The Company distributes its products within domestic market and to overseas markets, including Southeast Asia, Middle East and Africa.